Less Ads, More Data, More Tools Register for FREE

Pin to quick picksShield Thera Regulatory News (STX)

Share Price Information for Shield Thera (STX)

Share Price is delayed by 15 minutes
Get Live Data
5.75    -0.10 (-1.71%)
Bid:
5.70
Ask:
5.80
Spread: 0.10 (1.754%)
Market Cap: £61.50m
STX Live PriceLast checked at - London Stock Exchange

Intraday Shield Thera Share Chart

Form 8.3 - Shield Therapeutics plc

9 May 2023 11:04

Form 8.3 - Shield Therapeutics plc

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”)

1. KEY INFORMATION

(a) Full name of discloser:Jupiter Fund Management Plc
(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. 
(c) Name of offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offereeShield Therapeutics plc
(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: 
(e) Date position held: For an opening position disclosure, state the latest practicable date prior to the disclosure5th May 2023
(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer? If it is a cash offer or possible cash offer, state “N/A”No

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:1.5p Ordinary
 InterestsShort positions
 Number%Number%
(1) Relevant securities owned and/or controlled:37,146,9926.34  
(2) Cash-settled derivatives:    
(3) Stock-settled derivatives (including options) and agreements to purchase/sell:    
TOTAL:37,146,9926.34  

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b) Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:None
Details, including nature of the rights concerned and relevant percentages:None

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Class of relevant securityPurchase/saleNumber of securitiesPrice per unit
None   

(b) Cash-settled derivative transactions

Class of relevant securityProduct descriptione.g. CFDNature of dealinge.g. opening/closing a long/short position, increasing/reducing a long/short positionNumber of reference securitiesPrice per unit
NONE    
     

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of relevant securityProduct description e.g. call optionWriting, purchasing, selling, varying etc.Number of securities to which option relatesExercise price per unitTypee.g. American, European etc.Expiry dateOption money paid/ received per unit
NONE       

(ii) Exercise

Class of relevant securityProduct descriptione.g. call optionExercising/ exercised againstNumber of securitiesExercise price per unit
NONE    

(d) Other dealings (including subscribing for new securities)

Class of relevant securityNature of dealinge.g. subscription, conversionDetailsPrice per unit (if applicable)
None   

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”
NONE

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:(i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:If there are no such agreements, arrangements or understandings, state “none”
NONE

(c) Attachments

Is a Supplemental Form 8 (Open Positions) attached?NO

Date of disclosure:9th May 2023
Contact name:Jon Watson
Telephone number:0203 817 1672

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

Date   Source Headline
12th Jan 20232:40 pmRNSHolding(s) in Company
12th Jan 20232:15 pmRNSHolding(s) in Company
9th Jan 20235:10 pmRNSPartial AOP Loan Conversion
9th Jan 20233:56 pmRNSHolding(s) in Company
9th Jan 20233:25 pmRNSHolding(s) in Company
5th Jan 20233:45 pmRNSResult of General Meeting & Open Offer
28th Dec 20227:00 amRNSTotal Voting Rights Update
28th Dec 20227:00 amRNSPDMR Transaction Notification
16th Dec 20227:00 amRNSPublication of Circular &Notice of General Meeting
13th Dec 20223:45 pmRNSSuccessful completion of US$18.5m Equity Fundraise
13th Dec 20227:02 amRNSInvestor presentation
13th Dec 20227:01 amRNSPlacing & Subscription to raise approx. US$18m
13th Dec 20227:00 amRNSCollaborative Sales Agreement signed with Viatris
31st Oct 20227:00 amRNSRepublic of Korea update
27th Oct 20227:00 amRNSShelf-life for Accrufer® extended to 48 months
24th Oct 20227:00 amRNSData presented at ACG Annual Scientific Meeting
30th Sep 20227:00 amRNSBlock Listing 6 Monthly Return
15th Sep 20221:52 pmEQSHardman & Co Research on Shield Therapeutics (STX): Accrufer momentum building
14th Sep 20222:17 pmRNSHolding(s) in Company
8th Sep 20227:00 amRNSHalf-year Report
1st Sep 20222:20 pmRNSHolding(s) in Company
1st Sep 20227:00 amRNSLaunch of new corporate brand and website
31st Aug 20222:00 pmRNSTotal Voting Rights Update
31st Aug 202211:00 amRNSNotice of Interim Results
30th Aug 20229:30 amRNSHolding(s) in Company
12th Aug 202211:45 amEQSHardman & Co: Q&A on Shield Therapeutics (STX): Upside potential is enormous
9th Aug 20224:45 pmRNSGrant of share options
1st Aug 20227:00 amRNSCompletion of Loan Agreement & Partial Conversion
27th Jul 20224:20 pmRNSResults of 2022 General Meeting
27th Jul 20224:15 pmRNSResults of 2022 Annual General Meeting
26th Jul 20227:15 amEQSHardman & Co Research: Shield Therapeutics (STX): Looking to accelerate positive signals in the US
14th Jul 20227:00 amRNSNew Drug Submission accepted by Health Canada
8th Jul 20227:00 amRNSNotice of General Meeting
30th Jun 20224:41 pmRNSSecond Price Monitoring Extn
30th Jun 20224:36 pmRNSPrice Monitoring Extension
30th Jun 20222:06 pmRNSSecond Price Monitoring Extn
30th Jun 20222:00 pmRNSPrice Monitoring Extension
30th Jun 202211:05 amRNSSecond Price Monitoring Extn
30th Jun 202211:00 amRNSPrice Monitoring Extension
30th Jun 20229:05 amRNSSecond Price Monitoring Extn
30th Jun 20229:00 amRNSPrice Monitoring Extension
30th Jun 20227:01 amRNS2021 Annual Report and 2022 AGM Notice
30th Jun 20227:00 amRNSBusiness Update, Final Results&Financing Agreement
29th Jun 20227:00 amRNSNotice of Results
28th Jun 20224:40 pmRNSSecond Price Monitoring Extn
28th Jun 20224:35 pmRNSPrice Monitoring Extension
28th Jun 20222:05 pmRNSSecond Price Monitoring Extn
28th Jun 20222:00 pmRNSPrice Monitoring Extension
29th Apr 20227:00 amRNSTotal Voting Rights Update
31st Mar 20223:50 pmRNSBlock Listing Application

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.